172 related articles for article (PubMed ID: 16098254)
21. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
[TBL] [Abstract][Full Text] [Related]
22. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
23. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
[TBL] [Abstract][Full Text] [Related]
24. The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116.
Dabkeviciene D; Jonusiene V; Zitkute V; Zalyte E; Grigaitis P; Kirveliene V; Sasnauskiene A
Med Oncol; 2015 Dec; 32(12):258. PubMed ID: 26519257
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
[TBL] [Abstract][Full Text] [Related]
26. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
[TBL] [Abstract][Full Text] [Related]
27. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Schirripa M; Loupakis F; Cao S; Zhang W; Yang D; Ning Y; Berger MD; Miyamoto Y; Suenaga M; Iqubal S; Barzi A; Cremolini C; Falcone A; Battaglin F; Salvatore L; Borelli B; Helentjaris TG; Lenz HJ
Cancer; 2017 Nov; 123(22):4506-4514. PubMed ID: 28708932
[TBL] [Abstract][Full Text] [Related]
28. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
29. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
30. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
31. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
Gordon MA; Zhang W; Yang D; Iqbal S; El-Khouiery A; Nagashima F; Lurje G; Labonte M; Wilson P; Sherrod A; Ladner RD; Lenz HJ
Pharmacogenomics; 2011 Jan; 12(1):27-39. PubMed ID: 21174620
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
[TBL] [Abstract][Full Text] [Related]
33. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
[TBL] [Abstract][Full Text] [Related]
34. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
35. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
37. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
38. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
[TBL] [Abstract][Full Text] [Related]
39. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
40. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
